Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives

Area of Science:

• Cardiology and Pulmonary Medicine
• Vascular Biology
• Translational Research

Background:

• Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by remodeling, leading to right heart failure and death.
• Advances in understanding PAH pathobiology, epidemiology, and treatment have improved outcomes, yet challenges persist.
• Key signaling pathways, including TGF-β, are implicated in PAH vascular remodeling, with sotatercept targeting the activin pathway.

Purpose of the Study:

• To review recent advances in PAH pathobiology, epidemiology, diagnosis, and treatment.
• To highlight the role of sotatercept as a novel anti-remodeling therapy.
• To identify persistent gaps in PAH management and future research directions.

Main Methods:

• Literature review and synthesis of current research on PAH.
• Analysis of epidemiological trends and diagnostic challenges.
• Evaluation of current and emerging therapeutic strategies, including sotatercept and lung transplantation.

Main Results:

• PAH epidemiology shows a shift towards older adults with comorbidities; methamphetamine-associated PAH is rising in North America.
• Diagnosis is often delayed, emphasizing the need for earlier identification tools like AI-assisted diagnostics.
• Sotatercept demonstrated improvements in hemodynamics and clinical outcomes, while upfront combination therapy and parenteral prostacyclins are standard for high-risk patients.

Conclusions:

• Sotatercept represents a significant advancement in PAH treatment by targeting vascular remodeling.
• Despite progress, earlier detection, management of comorbidities, and novel therapies for right ventricular failure are needed.
• Continued research and clinical trials are essential to achieve normal survival and quality of life for PAH patients.